Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.

Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.
Metastatic Colorectal Cancer
DRUG: Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|DRUG: Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan
Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab., 12 months after inclusion
PRIMARY OBJECTIVE: Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab

SECONDARY OBJECTIVE(S):

* Overall Survival
* Progression free survival
* Secondary resection
* Early tumor shrinkage (ETS)
* Depth of response (DpR)
* Safety profile (NCI-CTCAE v4.03 classification)
* Diagnostic performance of ccfDNA analysis compared to the tumor-tissue analysis (current gold standard)